Tissue Regenix strengthens position in post-acute wound care market with Medicare coverage for Dermapure

Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, announces that it has further strengthened its position within the post-acute wound care market as Tissue Regenix Wound Care Inc. has received further approval for DermaPure® under Medicare administrator, First Coast Service Options Inc. ("First Coast") whose jurisdiction includes Florida, Puerto Rico and the US Virgin Islands.

With this approval, Tissue Regenix Wound Care Inc. increases the number of Medicare beneficiaries to whom DermaPure® is available by 2.5m. With prior approvals from Noridian Health Care Solutions, Palmetto GBA, Novitas Solutions and CGS Administrators within the first seven months of market availability, DermaPure® is now available across 31 States, the US Virgin Islands and Puerto Rico and is accessible to c.65% of the 37m beneficiaries enrolled under the Medicare programme.

The Medicare programme within the United States acts a national insurance programme available to citizens of 65 and over, subsidising healthcare costs and providing access to treatment that may otherwise not be available. This approval by First Coast means that medical establishments under their jurisdiction can now seek reimbursement for the use of DermaPure® in outpatient scenarios.

Antony Odell, CEO of Tissue Regenix Group plc:

"Tissue Regenix continues to make significant progress in securing these critical approvals, not only allowing more patients to benefit from improved clinical outcomes, but demonstrating both the efficacy of the product and the strength of our hybrid commercialisation strategy.

"Commercial interest in DermaPure® continues to grow and I look forward to announcing further LCD coverage approvals and expanding commercial payer coverage in due course."